CLE

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	15

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

trials per page:

Showing 1 to 10 of 15 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04643327 (ClinicalTrials.gov)	February 9, 2021	18/11/2020	Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease	Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficac ...	Parkinson Disease;Mild Cognitive Impairment;Memory Impairment	Drug: Levetiracetam;Drug: Placebo	The University of Queensland	Johns Hopkins University;Cleveland Clinic Lou Ruvo Center for Brain Health;Royal Brisbane and Women' ...	Recruiting	N/A	N/A	All	28	Phase 2	Australia
2	EUCTR2020-003796-17-GB (EUCTR)	22/10/2020	01/09/2020	A study to look at the effect of CST-103 or CST-139 on blood flow in the brain and on memory.	An Open-Label Brain Imaging and Cognition Study to Determine Changes in Cerebral Perfusion and Cogni ...	Patients with Mild Cognitive Impairment or Parkinson’s Disease MedDRA version: 21.1;Level: LLT;Class ...	Trade Name: Spiropent Product Name: Clenbuterol HCl Product Code: CST-103 INN or Proposed INN: CLENBUTE ...	CuraSen Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	32	Phase 2	United Kingdom
3	NCT03815916 (ClinicalTrials.gov)	December 19, 2019	18/1/2019	31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Dis ...	A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spec ...	Parkinson's Disease	Drug: Gold Nanocrystals	Clene Nanomedicine	University of Texas Southwestern Medical Center	Completed	30 Years	80 Years	All	13	Phase 2	United States
4	NCT02934919 (ClinicalTrials.gov)	December 2016	14/10/2016	Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Labe ...	Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Labe ...	Impulse Control Disorders;Parkinson Disease	Drug: Nalmefene	University Hospital, Clermont-Ferrand	NULL	Not yet recruiting	18 Years	80 Years	Both	30	Phase 2	France
5	NCT02641054 (ClinicalTrials.gov)	February 2016	7/12/2015	Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease	Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0 ...	Idiopathic Parkinson Disease	Drug: CVXL-0107;Drug: Placebo;Drug: Levodopa	CleveXel Pharma	NULL	Completed	40 Years	75 Years	All	21	Phase 2	France
6	NCT02046434 (ClinicalTrials.gov)	January 2014	23/1/2014	Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain	Phenylbutyrate Response As a Biomarker for Alpha-Synuclein Clearance From Brain	Parkinson's Disease	Drug: Glycerol Phenylbutyrate	University of Colorado, Denver	NULL	Active, not recruiting	21 Years	80 Years	All	40	Phase 1	United States
7	NCT02263235 (ClinicalTrials.gov)	October 8, 2013	18/9/2014	In Vivo Alzheimer Proteomics	Use of Targeted Quantitative Proteomics and Metabolic Labelling With Stable Isotopes for the Diagnos ...	Probable Alzheimer Disease;Parkinson Disease;Neurological Disease Without Cognitive Degradation;Brai ...	Biological: administration of stable isotope-labelled leucine-;Other: collection of CSF, blood, urin ...	University Hospital, Montpellier	Assistance Publique - Hôpitaux de Paris;University Hospital, Clermont-Ferrand;International Atomic E ...	Terminated	55 Years	85 Years	All	89	N/A	France
8	NCT01765257 (ClinicalTrials.gov)	June 2013	8/1/2013	Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease b ...	Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease b ...	Drug-naïve Patients With Parkinson's Disease;Apathy	Drug: AZILECT®;Drug: Placebo	University Hospital, Clermont-Ferrand	H. Lundbeck A/S, TEVA;CHU Purpan (Toulouse);Hôpital Haut-Levêque (Pessac);Centre Hospitalier de la C ...	Not yet recruiting	30 Years	70 Years	Both	50	Phase 4	France
9	EUCTR2009-017238-39-DE (EUCTR)	16/09/2010	28/07/2010	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety S ...	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety S ...	Idiopathic Parkinson’s Disease (paralysis agitans) MedDRA version: 14.0;Level: PT;Classification cod ...	Product Name: IPX066 Product Code: IPX066-95 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODO ...	Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)	NULL	Not Recruiting			Female: yes Male: yes	96	Phase 3	France;Belgium;Germany;Italy
10	EUCTR2009-017238-39-FR (EUCTR)	15/09/2010	09/07/2010	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) in Advanced Parkinson’s Disease	Idiopathic Parkinson’s Disease (paralysis agitans) MedDRA version: 12.1;Level: LLT;Classification co ...	Product Name: IPX066 Product Code: IPX066-95 INN or Proposed INN: CARBIDOPA INN or Proposed INN: LEVODO ...	Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)	NULL	Not Recruiting			Female: yes Male: yes	56	Phase 3	France;Belgium;Germany;Italy

First Previous1 2Next Last